GlaxoSmithKline in $1.5 billion collaboration deal

GlaxoSmithKline announced a deal on Thursday with the privately held drug research firm ChemoCentryx to discover, develop and market novel medicines for a variety of inflammatory disorders. As part of the deal ChemoCentryx will receive an upfront payment of $63.5 million and will be eligible to earn milestone payments up to, potentially, $1.5 billion. Under the agreement, Mountain View, CA-based ChemoCentryx will also get a double digit royalty percentage on collaboration product sales, and an investment from GlaxoSmithKline should the company go public. ChemoCentryx's Traficet-EN, which is in late stage development for the treatment of inflammatory bowel disease, is included in the agreement.
You must be a registered member of MMM to post a comment.

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.